Arcturus Therapeutics Holdings (ARCT) Other Accumulated Expenses (2018 - 2019)
Arcturus Therapeutics Holdings' (ARCT) quarterly Other Accumulated Expenses came in at $560000.0 in Q3 2019, down 55.34% on a QoQ basis from $1.3 million in Q2 2019.
Powered by 
Analysis
Arcturus Therapeutics Holdings (ARCT) Other Accumulated Expenses (2018 - 2019) Analysis & Trends
Arcturus Therapeutics Holdings (ARCT) has 2 years of Other Accumulated Expenses data on file, last reported at $560000.0 in Q3 2019.
- Quarterly Other Accumulated Expenses changed N/A year-over-year to $560000.0 in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $560000.0 (changed N/A YoY) and the FY2018 annual result came in at $674000.0, changed N/A from the prior year.
- Other Accumulated Expenses slipped to $560000.0 in Q3 2019, from $1.3 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $1.3 million in Q2 2019 to a low of $560000.0 in Q3 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Arcturus Therapeutics Holdings | 449.65 Mn | 258.17 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2019 | 560,000.00 |
| Jun 30, 2019 | 1.25 Mn |
| Dec 31, 2018 | 674,000.00 |